Ninlaro

Active Ingredient(s): Ixazomib
FDA Approved: * November 20, 2015
Pharm Company: * MILLENNIUM PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ninlaro Overview

Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer,[2] in combination with other drugs. It is taken by mouth in the form of capsules. Common side effects include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative. The drug was developed by Take...

Read more Ninlaro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ixazomib

Recent Ninlaro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ixazomib
  • Capsule: 2.3mg, 3mg, 4mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ninlaro: (6 results)

Sorted by National Drug Code
  • 63020-078 Ninlaro 2.3 mg Oral Capsule by Millennium Pharmaceuticals, Inc.
  • 63020-079 Ninlaro 3 mg Oral Capsule by Millennium Pharmaceuticals, Inc.
  • 63020-080 Ninlaro 4 mg Oral Capsule by Millennium Pharmaceuticals, Inc.
  • 63020-230 Ninlaro 2.3 mg Oral Capsule by Millennium Pharmaceuticals, Inc.
  • 63020-390 Ninlaro 3 mg Oral Capsule by Millennium Pharmaceuticals, Inc.
  • 63020-400 Ninlaro 4 mg Oral Capsule by Millennium Pharmaceuticals, Inc.

Other drugs which contain Ixazomib or a similar ingredient: (1 result)